Short answer
CODEXIS, INC. (CDXS) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $19M (up 124.0% year over year) with net income of −$8M.
Q3 2026 key financials · XBRL
- Revenue
- $19M
- +124.0% YoY · +29.2% QoQ
- Net income
- −$8M
- +58.6% YoY · +32.3% QoQ
- Operating margin
- -38.6%
- EPS (diluted)
- −$0.07
- +68.2% YoY · +46.2% QoQ
Source: XBRL data from the CODEXIS, INC. (CDXS) Q3 2026 10-Q on SEC EDGAR. USD.
CODEXIS, INC. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $19.3M, up $10.7M YoY from $8.6M
- Product revenue $15.7M, up $8.9M, driven by $8.4M higher commercial pharmaceutical enzyme sales
- Product gross margin 74% vs 64% YoY, reflecting a shift toward more profitable products
- Operating loss $7.4M vs $18.9M YoY, net loss $8.1M vs $19.6M
- Cash $29.2M vs $50.8M, operating cash use $30.6M, July equity offering net proceeds $24.9M
Risk Factors
- Newly highlighted compliance risk: U.S. BIOSECURE Act enacted December 2025 could restrict counterparties deemed biotechnology companies of concern
- Most material operational update: ECO GMP Manufacturing Center retrofit begins Q4 2026, with potential permitting delays and cost overruns
- Regulatory risk: FDA could reject the Company’s FDCA exemption, requiring cGMP compliance and potentially halting product distribution
- Market risk: customers contributed 48% of nine-month revenue, increasing exposure to customer losses or reduced purchases
- Financial risk: Trinity LSA includes $7.5 million available through December 15, 2027 and liquidity covenant tied to $400.0 million market capitalization
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other CODEXIS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.